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Fragment Growing Exploiting Dynamic 
Combinatorial Chemistry of Inhibitors of the 
Aspartic Protease Endothiapepsin 
 
 
Here, we have demonstrated that the novel combination of fragment-growing 
and dynamic combinatorial chemistry (DCC) is a highly powerful strategy to 
grow a fragment into a more potent, non-covalent inhibitor of the aspartic 
protease endothiapepsin. We have designed a library of acylhydrazones using 
fragment-growing starting from a known fragment in complex with 
endothiapepsin. We have used DCC and a fluorescence-based enzymatic assay 
to identify the best hit(s) from the dynamic combinatorial libraries, disp laying 
double-digit micromolar inhibition of endothiapepsin. In addition, each DCC 
experiment requires only very small amounts of protein compared with 
established analytical methods and the protein needs to be in the assay mixture 
only for a short period of time, making this protocol ideal for precious and 
unstable proteins. These results constitute a proof of concept that the 
combination of fragment growing and DCC is a powerful and efficient strategy 





This chapter is adapted from the original paper: 
M. Mondal, D. E. Groothuis, A. K. H. Hirsch, MedChemComm., 2015, 6, 1267–





In fragment-based drug design (FBDD), once a fragment has been identified, it 
has to be optimized to a lead compound by fragment growing or linking. On the 
one hand, fragment growing has become the preferred fragment-optimization 
strategy.1–6 Preserving the binding modes of two fragments bound to adjacent 
pockets, as required in fragment linking, is considered attractive given the 
potential for super-additivity but at the same time very challenging.7 On the 
other hand, fragment growing is time-consuming as it requires synthesis of 
derivatives and validation of their binding mode at each step of the fragment-
optimization cycle. To overcome this hurdle, we developed a strategy in which 
we combine fragment growing with dynamic combinatorial chemistry (DCC) 
for the efficient optimization of a fragment to a hit. There are numerous reports 
of DCC to facilitate hit/lead-identification or -optimization.8 A proof of concept 
for fragment linking facilitated by DCC has been provided retrospectively when 
letting disconnected known hydrazine inhibitors reassemble in the presence of 
crystals of the protein target.9 Furthermore, linking of an intermediate derived 
from biosynthesis to fragments designed to occupy adjacent pockets by 
disulfide-based DCC10 as well as covalent tethering have been reported over the 
past decade.11,12,13 FBDD in combination with DCC has, however, never been 
explicitly reported for conventional fragment growing in a strict FBDD context. 
We report here a fluorescence-based enzymatic assay to conveniently screen a 
dynamic combinatorial library (DCL) for active inhibitors, which requires small 
amounts of the protein target for a short period of time, making it ideally suited 
for precious and unstable proteins.14 We will employ the combination of FBDD 
and acylhydrazone-based DCC for the efficient fragment-to-hit optimization of 
inhibitors of the aspartic protease endothiapepsin.  
5.2 Results and Discussion 
5.2.1 FBDD: fragment growing 
For our studies, we used the crystal structure of endothiapepsin in complex with 
fragment 1 (Protein Data Bank (PDB) code: 3PCW).15 Fragment 1 was found to 
inhibit endothiapepsin during a fragment-based screening campaign.15 As 
shown in Figure 1, 1 is engaged in three charged H bonds with the catalytic 
dyad consisting of residues D35 and D219 by using its amidine group. Except 




(Mw) of 261 Da, three H-bond donors, two H-bond acceptors, one freely 
rotatable bond and a total polar surface area (TPSA) of 49.9 Å2. The fact that 1 
shows 45% inhibition of endothiapepsin at a concentration of 1 mM, combined 
with its promising physicochemical properties, and that it only has 13 heavy 
atoms encouraged us to choose it as a starting point for optimization into an 
inhibitor of endothiapepsin. Fragment 1 occupies the S2 and part of the S1 and 
S1' pockets of endothiapepsin and addresses the catalytic dyad through charged 
H-bonding interactions (Figure 1a).  
 
Figure 1. a) X-ray crystal structure of endothiapepsin in complex with fragment 1 bound in the 
active site (PDB code: 3PCW).15 Color code: (protein surface) C: gray, O: red and N: blue; 
(fragment skeleton) C: green, N: blue and F: cyan. b) Superimposition of MOLOC-generated 
molecular models of potential acylhydrazone inhibitors featuring direct H-bonding interactions 
with the catalytic dyad (D35 and D219) in the active site of endothiapepsin (PDB code: 3PCW). 
Color code: (protein skeleton) C: gray; (inhibitor skeletons) C: green, violet, purple, orange, and 
yellow, N: blue, F: cyan, and O: red. Hydrogen bonds below 3.4 Å are shown as black, dashed 
lines. 
By using the molecular-modeling software Moloc16 and the FlexX docking 
module in the LeadIT suite,17 we designed a derivative of 1, in which the 
amidine group is replaced with an α-amino group to address both D35 and D219 
of the catalytic dyad through H-bonding interactions. As we have already shown 
that the acylhydrazone moiety is a suitable central scaffold to address the 
catalytic dyad of endothiapepsin,18 we decided to use an acylhydrazone moiety 
to grow 1 towards the S1 and S3 pockets. We introduced an acylhydrazone 
linker pointing towards the S1 & S3 pockets. According to our modeling, the 
NH group of the newly designed acylhydrazone moiety is engaged in an H-
bonding interaction with D35, while the carbonyl group of the acylhydrazone 
linker accepts an H bond from the backbone of G80. Careful investigation of 
known co-crystal structures of endothiapepsin15 and hotspot analysis19 of the 




substituents can be introduced through the aldehyde of the acylhydrazone 
linker, which can be involved in hydrophobic interactions with L125, I122, 
F116 and Y79 in the S1 & S3 pockets (Figure 1b). Based on molecular 
modeling and docking studies, we selected a series of nine acylhydrazone-based 
inhibitors. All the derivatives can be conveniently synthesized starting from 
hydrazide 2 by reacting it with nine aldehydes (3a–11a).  
5.2.2 Synthesis of building block 
While all aldehydes are commercially available, we synthesized 2 via an 
asymmetric Strecker reaction starting from commercially available para-
trifluoromethylbenzaldehyde (11a, Scheme 1). α-Aminonitrile 16 was formed 
from aldehyde 11a and chiral auxiliary 15 in 48% yield and 97% de.20 
Hydrolysis of α-aminonitrile 16 afforded α-arylglycine 17 in 92% yield, which 
was esterified with saturated methanolic-HCl to the corresponding methyl ester 
hydrochloride 18 in 43% yield followed by treatment with hydrazine 
monohydrate to afford the hydrazide building block 2 in 80% yield.  
 
Scheme 1. Synthesis of hydrazide 2 using the asymmetric Strecker reaction starting from para-
trifluorobenzaldehyde 11a. 
5.2.3 Formation and analysis of DCL 
We set up nine DCLs, each containing hydrazide 2 (Scheme 2a) and one of the 
nine aldehydes 3a–11a to form the corresponding acylhydrazones 3h–11h 
(Scheme 2b). We used a fluorescence-based enzymatic activity assay to 
conveniently screen the DCLs for active inhibitors as this method requires very 
small amounts of protein.14 In the assay, we used the fluorogenic substrate of 




which is hydrolyzed by endothiapepsin and generates two fluorescent 
fragments, namely 13 and 14, enabling convenient spectrophotometric 
monitoring (Scheme 3). 
 
Scheme 2. (a) Generation of acylhydrazone-based inhibitors 3h–11h from fragment 1. (b) 
Generation of acylhydrazone-based DCLs from hydrazide 2 and structures of the individual 
aldehydes 3a–11a for screening by a fluorescence-based activity assay. 
 
Scheme 3. Hydrolysis of fluorogenic HIV-protease substrate 12 (2-aminobenzoyl-Thr-Ile-Nle-





Having investigated the DCLs using the fluorescence-based assay, we identified 
a total of two DCLs out of nine displaying considerably higher inhibition of 
endothiapepsin than 1, showing 75% (IC50 = 407 μM) and 79% (IC50 = 252 μM) 
inhibition at an inhibitor concentration of 1 mM (based on the acylhydrazones 
formed in situ) for the DCLs 3a + 2 and 9a + 2, respectively (Figure 2). In the 
DCLs, three components (aldehyde, hydrazide and acylhydrazone) are in 
equilibrium. As a result, full conversion to the corresponding acylhydrazones is 
not ensured. In addition, the excess hydrazide building blocks might compete 
for binding. As a result, the IC50 values determined this way are expected to be 
higher than those for isolated and purified compounds.  
 
Figure 2. a) Bar graph of fluorescence-based assay results of all nine DCLs as well as fragments 1 
and 2. The % inhibition (mM) is plotted for each DCL as well as fragments 1 and 2. b) IC50 
inhibition curves of DCLs 3a + 2 and 9a + 2 identified by the fluorescence-based screening of 
DCLs. 26 experiments were performed for each measurement and only six experiments were 
considered to calculate the initial slope (n = 6), 11 different concentrations of inhibitor were used 





5.2.4 Synthesis and biological evaluation of identified 
acylhydrazones 
To determine the accurate IC50 values of the hit compounds identified from 
screening the DCLs, we synthesized the corresponding acylhydrazones 3h and 
9h individually (Scheme 4). By adopting the same fluorescence-based enzyme 
activity assay, we confirmed the results from screening of the DCLs and 
established that acylhydrazones 3h and 9h display IC50 values of 210 μM and 
85 μM, respectively (Figure 3). We calculated the experimental Gibbs free 
energies of binding (ΔGEXPT (3h) = −23 kJ mol−1, ΔGEXPT (9h) = −25 kJ mol−1) 
and ligand efficiencies (LE (3h) = 0.24, LE (9h) = 0.27) from the IC50 values 
using the Cheng–Prusoff equation,21 which correlate with the calculated values 
from the scoring function HYDE in the LeadIT suite (∆GHYDE(3h) = −23 kJ 
mol−1, ∆GHYDE (9h) = –30 kJ.mol–1. 
 
 
Scheme 4. Synthesis of acylhydrazones (a) 3h and (b) 9h, identified by fluorescence-based 
screening of DCLs.  
As shown in Figure 4, we designed 3h and 9h so as to bind in a similar way, 
addressing the catalytic dyad using their α-amino group to form direct H-bonds 
with D35 and D219. The amide groups of both compounds donate an H bond to 
D35. The carbonyl groups of the acylhydrazone moieties also accept an H bond 
from the backbone amide of G80. The para-trifluoromethylphenyl group of both 
acylhydrazones occupies the S2 and part of the S1' pockets of endothiapepsin 
and is involved in several hydrophobic interactions with I300, I302, I304, I217 




cyclopentyl groups of the acylhydrazones, in turn, fill the S3 pocket and are 
engaged in hydrophobic contacts with L125, I122, F116 and Y79. 
 
 
Figure 3. IC50 inhibition curves of 3h (IC50 = 210 ± 32 μM) and 9h (IC50 = 85 ± 8 μM). Each 
inhibitor was measured in duplicate and the errors are given in standard deviations (SD), 26 
experiments were performed for each measurement and only six experiments were considered to 
calculate the initial slope (n = 6), 11 different concentrations of inhibitor were used start ing at 
1 mM.  
 
Figure 4. Predicted full binding modes of (a) 3h and (b) 9h in the catalytically active site of 
endothiapepsin (PDB code: 3PCW).15 Color code: (enzyme skeleton) C: gray; (inhibitor skeleton) 
C: yellow and violet, N: blue, O: red and F: cyan. Hydrogen bonds below 3.4 Å are shown as 





In conclusion, we have demonstrated for the first time that the combination of 
fragment growing and DCC is a powerful technique for the rapid optimization 
of initial fragment to hits for the aspartic protease endothiapepsin. Moreover, by 
using a fluorescence-based assay, we could directly screen the DCLs for active 
inhibitors. The advantages of this approach are that only very small amounts of 
protein are required compared with established analytical methods and that the 
protein only needs to be in the assay mixture for a short period of time, making 
this protocol ideal for precious and unstable proteins. Among the 
acylhydrazones identified, the most potent inhibitor 9h displays an IC50 value of 
85 μM. This synergistic combination of computational and analytical 
methodologies proved to be successful for the efficient development of 
inhibitors of the aspartic protease endothiapepsin and could be applied to a wide 
range of targets. 
5.4 Experimental Section 
5.4.1 Fluorescence-based assay for DCL screening 
Stock solutions of each aldehyde 3a–11a and hydrazide 2 were prepared. Nine 
DCLs were synthesized, each containing one aldehyde (2 μL, stock solution 
200 mM in DMSO) and one hydrazide (2.2 μL, stock solution 200 mM in 
DMSO) and sodium acetate buffer (47 μL, 0.1 M, pH 4.6, containing 0.001% 
Tween  20). All nine DCLs were left to stand at room temperature for 24 h with 
occasional shaking. As substrate, Abz-Thr-Ile-Nle-p-nitro-Phe-Gln-Arg-NH2 
(12, purchased from Bachem) was used for the fluorescence screening assay. 
The assay was performed with flat bottom 96-well microplates (purchased from 
Greiner Bio-One) using a Synergy Mx microplate reader at an excitation 
wavelength of 337 nm and an emission wavelength of 414 nm. The Km of the 
substrate toward endothiapepsin was known, 1.6 μM.15 The assay buffer (0.1 M 
sodium acetate buffer, pH 4.6, containing 0.001% Tween 20) was premixed 
with the substrate and each of the DCLs individually; endothiapepsin was added 
directly before the measurement. The final reaction volume was 200 μL 
containing 0.4 nM endothiapepsin, 1.8 μM substrate, 1.05 mM of acylhydrazone 
(based on full conversion) and 2.1% DMSO. In the same way, blanks were 
prepared using DMSO instead of the DCL stock solutions. As the substrate is a 
fluorogenic substrate, during measurement the fluorescence increased because 




in the DCLs-containing wells were compared to the initial slope of the blanks 
for data analysis.  
5.4.2 Fluorescence-based inhibition assay 
Stock solutions (100 mM in DMSO) were prepared for both acylhydrazones 3h 
and 9h (mixture of E/Z isomers).  
For rest of the inhibition assay, see Chapter 2, Section 2.4.2. 
5.4.3 Modeling and Docking 
One X-ray crystal structure of complexe of endothiapepsin (PDB codes: 3PCW) 
was used for our modeling.15 
For rest of the modeling and docking studies, see Chapter 2, Section 2.4.3. 
4.4.4 General experimental details 




In an adaptation of a literature procedure,20 15 
(893 mg, 4.76 mmol) and NaCN (245 mg, 
5 mmol) were dissolved in H2O (8.3 mL). To the 
mixture, aldehyde 11a (829 mg, 4.76 mmol) and 
MeOH (8.3 mL) were added. The reaction mixture 
was stirred for 19 h and diluted with H2O (20 mL). The mixture was extracted 
with CH2Cl2 (5 x 10 mL) and the combined CH2Cl2 extracts were dried over 
Na2SO4, filtered and concentrated in vacuo. After concentration in vacuo, the 
mixture was dissolved in Et2O and by addition of saturated Et2O.HCl, a white 
crystalline solid was obtained. The solid was collected via filtration and washed 
with n-hexane. The solid corresponded mainly to the diastereomer 16 (97% de 
(signals from minor diastereomer were not reported), 839 mg, 48% yield). 
m.p. 144‒147 °C; δH(400 MHz; CD3OD) 7.87 (2 H, d, J = 8.4, ArH), 7.77 (2 H, 
d, J = 8.3, ArH), 7.48 (2 H, d, J = 8.8, ArH), 7.08 (2 H, d, J = 8.8, ArH), 5.39 
(1 H, s, CHCN), 4.63 (1 H, q, J = 6.8, CHCH3), 3.85 (3 H, s, OCH3), 1.75 (3 H, 




130.4, 127.9, 127.8 (q, J = 4), 116.2, 115.2, 60.1, 56.0, 50.8, 20.2; δF(376 MHz; 
CD3OD) –64.64, –64.63; IR (cm−1): 2943 (br), 2563 (br), 1517, 1323, 1131, 
1022, 836; Anal. Calcd for C18H18ClF3N2O (%): C 58.30, H 4.89, N 7.55. 
Found: C 58.01, H 4.85, N 7.49.  
 
(S)-2-Amino-2-(4-(trifluoromethyl)phenyl)acetic acid hydrochloride (17):  
Compound 16 (789 mg, 2.12 mmol) was treated with HCl 
(6 M, 30 mL), and the mixture was stirred under reflux for 
17 h. The reaction mixture was cooled to room 
temperature and extracted with Et2O (5 x 15 mL). The 
aqueous layer was concentrated in vacuo and a white solid appeared. The solid 
was suspended in CHCl3 using a sonicator and filtered to afford 17 (500 mg, 
92% yield) as a white solid. m.p. > 245 °C (decomposition); δH(400 MHz; 
CD3OD) 7.81 (2 H, d, J = 8.2, ArH),  7.72 (2 H, d, J = 8.2, ArH), 5.26 (1 H, s, 
CHNH2); δC(101 MHz; CD3OD) 170.0, 138.1, 132.8 (q, J = 3.73), 130.0, 127.3 
(q, J = 3.77), 126.6, 57.0; δF(376 MHz; CD3OD) –61.25; IR (cm−1): 3338 (br), 
1627 (br), 1088, 543; HRMS (ESI) calcd for C9H9F3NO2+ [M+H]+: 220.0585, 
found: 220.0580. 
 
(S)-Methyl 2-amino-2-(4-(trifluoromethyl)phenyl)acetate hydrochloride 
(18):  
Compound 17 (450 mg, 1.96 mmol) was converted to a 
methyl ester under reflux conditions in saturated 
MeOH.HCl (10 mL) and dry MeOH (20 mL) overnight. 
Concentrated the reaction mixture in vacuo, purified by 
CC (SiO2; 5% MeOH in CH2Cl2 afforded 18 (230 mg, 43% yield) as white 
solid. m.p. 163‒167 °C; δH(400 MHz; (CD3)2SO) 9.26 (3 H, br. s, +NH3), 7.86 
(2 H, d, J = 8.1, ArH),  7.77 (2 H, d, J = 8.1, ArH), 5.46 (1 H, s, CHNH2), 3.72 
(3 H, s, OCH3); δC(400 MHz; (CD3)2SO) 168.3, 137.1, 129.8 (d, J = 32), 123.0, 
129.6, 129.3, 125.8 (q, J = 3.64), 123.9 (d, J = 272), 54.8, 53.3; δF(376 MHz; 
(CD3)2SO) –61.09; IR (cm−1): 2849 (br), 2628 (br), 1747, 1326, 1129, 1070, 
1018, 520; HRMS (ESI) calcd for C10H11F3O2+ [M+H]+: 234.0742, found: 
234.0736. 
 
(S)-2-Amino-2-(4-(trifluoromethyl)phenyl)acetohydrazide (2):  
The title compound 2 was synthesized by adding 
N2H4.H2O (0.287 mL, 5.9 mmol) to 18 (200 mg, 




overnight at 85 °C. The reaction mixture was concentrated in vacuo, and the 
residue was taken up in CH2Cl2/i-PrOH (3:1) and placed in sonicator. The 
resulting suspension was filtered and dried to afford 2 (142 mg, 82% yield) as a 
light, pinkish solid. m.p. 130–132 °C; δH(400MHz; CD3OD) 7.69–7.61 (4 H, m, 
ArH), 4.52 (1 H, s, CHNH2); δC(101 MHz; CD3OD) 174.2, 146.8, 131.3, 131.0, 
128.8, 127.1, 126.6 (q, J = 3.84), 124.4, 58.8; δF(376 MHz; CD3OD) –64.08; IR 
(cm−1): 3291 (br), 2469 (br), 1627, 1613, 1322, 1173, 1075; HRMS (ESI) calcd 




The hydrazide 2 (50 mg, 0.215 mmol) was 
dissolved in MeOH, treated with benzaldehyde 
3a (28 mg, 0.258 mmol, 1.2 eq.), and the 
mixture was heated to reflux for 10 h. The 
reaction mixture was allowed to cool to room temperature and concentrated in 
vacuo. Purification by column chromatography (SiO2; MeOH/DCM 0:10→1:9) 
afforded the acylhydrazone 3h (27 mg, 40%) as a mixture of E and Z isomers 
(E:Z=55:45) as a white solid (purity by HPLC > 99%). m.p. 144–147 °C; 
δH(400 MHz; CD3OD) 8.16 (1 H, s, N=CH(E)), 7.86 (1 H, s, N=CH(Z)), 7.75 
(1 H, dd, J = 6.6, 3.1, ArH), 7.70–7.68 (3 H, m, ArH), 7.65–7.61 (2 H, m, ArH), 
7.43–7.37 (3 H, m, ArH), 5.56 (1 H, s, CHNH2(Z)), 4.64 (1 H, s, CHNH2(E)); 
δC(101 MHz; CD3OD) 175.7, 171.7, 150.7, 146.6, 146.4, 135.4, 135.2, 131.7, 
131.3, 129.9, 129.8, 129.2, 128.8, 128.8, 128.2, 126.7 (q, J = 3.83, E), 126.5 (q, 
J = 3.81, Z), 124.2, 59.0, 56.2; δF(376 MHz; CD3OD) –64.05, –64.09; IR 
(cm−1): 3204 (br), 3067 (br), 1661, 1324, 1112, 1067; HRMS (ESI) calcd for 
C16H15F3N3O+ [M+H]+: 322.1161, found: 322.1166. 
(S)-Methyl 2-((tert-butoxycarbonyl)amino)-2-(4-
(trifluoromethyl)phenyl)acetate  (19):  
To a solution of (S)-methyl 2-amino-2-(4-
(trifluoromethyl)phenyl)acetate-hydrochloride (18) (3.00 
g, 12.84 mmol) and triethylamine (3.25 g, 32.1 mmol, 
2.5 eq.), in a mixture of dioxane and H2O (1:1, 120 mL), 
Boc2O (3.36 g, 15.4 mmol, 1.2 eq.) was gradually added at 20 °C. After stirring 
at rt for 15 h, the mixture was concentrated in vacuo to a volume of about 
40 mL. After addition of EtOAc (120 mL), the organic layer was separated and 




aqueous NaCl solution (50 mL), dried over MgSO4, filtered and concentrated in 
vacuo to afford 19 as a white solid (2.10 g, 70%). m.p. 80‒85 °C; δH(400 MHz; 
CDCl3) 7.61 (2 H, d, J = 8.0, ArH), 7.50 (2 H, d, J = 8.0, ArH), 5.69 (1 H, br. s, 
CH), 5.39 (1 H, d, J = 6.6, NH), 3.73 (3 H, s, OCH3), 1.43 (9 H, s, (CH3)3); 
δC(101 MHz; CDCl3) 171.0, 154.9, 141.3, 131.0, 130.7, 127.7, 126.0 (q, J = 
3.36 ), 125.48, 122.8, 80.7, 57.4, 53.2, 28.5; δF(376 MHz; CDCl3) –62.72; IR 
(cm−1): 3375 (br), 2923 (br), 1746, 1684, 1520, 1329, 1160, 1110, 1069, 1020, 
842; HRMS (ESI) calcd for C15H19F3NO4+ [M+H]+: 334.1260, found: 334.1257. 
 
(S)-2-Amino-2-(4-(trifluoromethyl)phenyl)acetohydrazide (20):  
To a solution of 19 (2.00 g, 5.98 mmol) in ethanol 
(10 mL), hydrazine-monohydrate (2.39 g, 47.8 mmol, 
8 eq.) was added, and the mixture heated to reflux for 
2 h. After concentration in vacuo, water was poured 
onto the residue. After filtration, the white solid was dried in vacuo to obtain the 
product as a white solid (2 g, quant.). m.p. 70‒73 °C; δH(400 MHz; CD3OD) 
7.65 (2 H, d, J = 8.3, ArH), 7.60 (2 H, d, J = 8.3, ArH), 5.24 (1 H, s, CH), 1.44 
(9 H, s, (CH3)3); δC(101 MHz; CD3OD) 171.6, 157.4, 143.9, 131.4 (dd, J = 32.3, 
64.8), 129.2, 127.0, 126.7 (dd, J = 3.7, 7.5), 124.4, 81.2, 58.3, 28.8; δF(376 
MHz; CD3OD) –64.14; IR (cm−1): 3297 (br), 2977, 1663, 1325, 1122, 1068; 
HRMS (ESI) calcd for C14H19F3N3O3+ [M+H]+: 334.1373, found: 334.1377.   
 
(S)-2-Amino-N’-(cyclopentylmethylene)-2-(4-
(trifluoromethyl)phenyl)acetohydrazide trifluoro acetic acid (9h):  
To a solution of 20 (40 mg, 0.12 mmol) in 
MeOH (1 mL), cyclopentanecarboxaldehyde 9a 
(13 mg, 0.13 mmol, 1.1 eq.) was added, and the 
mixture heated to reflux for 20 min. The solvent 
was removed in vacuo affording the crude product 21 as a white solid, which 
was directly used for deprotection of the Boc group. The crude compound 21 
was dissolved in CH2Cl2 (2 mL), and HCl/Et2O (1 M, 1.2 mL, 1.2 mmol, 10 eq.) 
was added. The mixture was stirred at 20 °C for 15 h. The solvent was removed 
in vacuo and used the crude purified by HPLC (HPLC conditions: column, 
XTerra® Prep MS C18 10 μm, 150 mm × 7.8 mm; flow rate, 1 mL min−1; 
wavelength, 230 nm; temperature, 23 °C; method: water/acetonitrile 95:5 
→5:95 (0.1% TFA) for 25 min), which afforded 9h (5 mg) as a mixture of E 
and Z isomers (E:Z=23:77) as a white solid (purity by HPLC: 98%). m.p. 95–




N=CH(E)), 7.19 (1 H, d, J = 6.0, N=CH(Z)), 5.74 (1 H, s, CHNH2(Z)), 5.09 
(1 H, s, CHNH2(E)), 2.76–2.68 (1 H, m, CH(CH2)2(E)), 2.65–2.56 (1 H, m, 
CH(CH2)2(Z)), 1.91–1.29 (8 H, m, (CH2)4); δC(101 MHz; CD3OD) 168.8, 160.0, 
155.1, 138.5, 138.0, 132.9, 132.6, 130.6, 130.30, 130.0, 127.5 (q, J = 3.93, E), 
127.1 (q, J = 3.77, Z), 126.6, 123.9, 56.4, 56.1, 43.8, 43.5, 31.4, 31.0, 30.6, 
26.4, 26.1; δF(376 MHz; CD3OD) –64.43, –64.50, –64.51, –77.02; IR (cm−1): 
3284 (br), 2955 (br), 2471, 1627, 1325, 1128; HRMS (ESI) calcd for 
C15H19F3N3O+ [M+H]+: 314.1474, found: 314.1479.  
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